Zelira Therapeutics (ASX:ZLD) Total Liabilities : A$5.22 Mil (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Zelira Therapeutics Total Liabilities?

Zelira Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 was A$5.22 Mil.

Zelira Therapeutics's quarterly Total Liabilities declined from Dec. 2022 (A$2.62 Mil) to Jun. 2023 (A$2.18 Mil) but then increased from Jun. 2023 (A$2.18 Mil) to Dec. 2023 (A$5.22 Mil).

Zelira Therapeutics's annual Total Liabilities increased from Jun. 2021 (A$1.54 Mil) to Jun. 2022 (A$2.01 Mil) and increased from Jun. 2022 (A$2.01 Mil) to Jun. 2023 (A$2.18 Mil).

Zelira Therapeutics Total Liabilities Historical Data

The historical data trend for Zelira Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zelira Therapeutics Total Liabilities Chart

Zelira Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Liabilities

Get a 7-Day Free Trial

0.41

1.24

1.54

2.01

2.18

Zelira Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial															1.35	2.01	2.62	2.18	5.22

Zelira Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Zelira Therapeutics's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.884	+	(0.295	+	-5.5511151231258E-17
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2.18

Total Liabilities	=	Total Assets (A: Jun. 2023 )	-	Total Equity (A: Jun. 2023 )
	=	33.891	-	31.712
	=	2.18

Zelira Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.004	+	(0.212	+	6.3837823915947E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	5.22

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	3.229	-	-1.986
	=	5.22

Zelira Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Zelira Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Zelira Therapeutics (ASX:ZLD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zelira Therapeutics Ltd (ASX:ZLD) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ZLDAF:USA G1G:Germany

Address

101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000

Website

https://www.zeliratx.com

Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.

Zelira Therapeutics (ASX:ZLD) Headlines

No Headlines